During the observation period, there was no clinical implant failure and the suvival rate for implantation and maxillary sinus floor augmentation was 100 %. Histological examination in a previous report on maxillary sinus augmentation using β-TCP (Cerasorb®), Szabo et al. compared bilateral maxillary sinus augmentation in the same patients using β-TCP and iliac bone at 6 months after surgery and reported a new bone ratio of 36.5 % in the β-TCP group (control group: 38.3 % autogenous bone), and in a similar experiment, Suba et al. reported a new bone ratio of 32.4 % in the β-TCP group (control group: 34.7 % autogenous bone), which were similar outcomes to those for the autogenous bone. These histological examinations provided supporting evidence that during the year after grafting, β-TCP is gradually replaced by new bone over time [19–21]. Our clinical and radiographic examination of maxillary sinus floor augmentation using β-TCP suggests that β-TCP is a very useful synthetic bone substitute with very similar progress to autogenous graft. It is of our interest to further continue our long-term clinical study.